title: The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog.
abstract: OBJECTIVE
  Cisplatin is a DNA-damaging antitumor agent that is highly effective in treating ovarian cancer. It activates the p53/p21 pathway for its cytotoxic mode of action, but it does not induce p21-dependent cell cycle arrest in G1. Therefore, we investigated this paradox, and used the model analog DAP as a positive control for p21-dependent G1-arrest.
  
  
  METHODS
  Studies were conducted in p53-proficient ovarian A2780 tumor cells to examine Cdk activity, cell cycle distribution and DNA damage signaling after cisplatin or DAP in combination with the mitotic inhibitor nocodazole.
  
  
  RESULTS
  Cisplatin consistently induced transient S-phase arrest by inhibiting Cdk2/cyclin A complex in S-phase at 12 h and then a durable G2/M-arrest by inhibiting Cdc2/cyclin B complex at 12-18 h. These inhibitions were associated with Chk1 and Chk2 activation and resultant increase in inhibitory tyrosine phosphorylation of Cdk2 and Cdc2. Cisplatin also potently inhibited G1-phase Cdk4/cyclin D1 and Cdk2/cyclin E activities at ~18 h. In agreement, exposure of cisplatin-treated A2780, HCT-116(p53-/-) and HCT-116(p21-/-) tumor cells to nocodazole revealed limited G1-arrest that was dependent on p53 and p21. In contrast, the durable G1-arrest by DAP, which failed to activate Chk1 and Chk2, was unaffected by nocodazole.
  
  
  CONCLUSIONS
  Cisplatin induced G1-arrest, but at an attenuated level. This was primarily due to orchestration of Cdk inhibition in S-phase first, then in G2, and finally in G1 that effectively blocked cells in G2 and prevented cells from progressing and arresting in G1. These studies demonstrate that cisplatin unequivocally activates G1-checkpoint response, but the fidelity of G1-arrest is compromised by Chk1/2 activation and checkpoint response in S- and G2/M-phase.
authors: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors: Guangan
authors: G
authors: He
authors: Jian
authors: J
authors: Kuang
authors: Abdul R
authors: AR
authors: Khokhar
authors: Zahid H
authors: ZH
authors: Siddik
references: J Clin Oncol. 2000 Dec 1;18(23):3936-45
references: 11099323
references: Mol Cell Biol. 2001 Feb;21(4):1066-76
references: 11158294
references: J Cancer Res Clin Oncol. 2003 Dec;129(12):709-18
references: 14513366
references: J Clin Oncol. 2005 Jul 10;23(20):4499-508
references: 16002840
references: J Biol Chem. 2003 Aug 29;278(35):32507-16
references: 12748190
references: Cell Growth Differ. 1992 Jan;3(1):43-52
references: 1534688
references: Br J Cancer. 1994 Jan;69(1):93-100
references: 8286217
references: Cancer Res. 2004 Jan 1;64(1):356-62
references: 14729645
references: Exp Cell Res. 2005 Jan 15;302(2):162-9
references: 15561098
references: J Cell Biochem. 2004 Feb 1;91(2):223-31
references: 14743382
references: Cancer Res. 1995 May 1;55(9):1842-6
references: 7728750
references: Gene Anal Tech. 1988 Mar-Apr;5(2):22-31
references: 3192155
references: Genes Dev. 1997 Apr 1;11(7):847-62
references: 9106657
references: J Biol Chem. 2006 Nov 17;281(46):34742-50
references: 16923815
references: Oncogene. 2004 Jan 29;23(4):973-80
references: 14749764
references: Clin Cancer Res. 1999 Mar;5(3):655-63
references: 10100719
references: Cell Cycle. 2009 Sep 15;8(18):3039-50
references: 19713747
references: BMC Mol Biol. 2010 Jun 24;11:49
references: 20576112
references: Cancer Res. 1996 Nov 1;56(21):4881-6
references: 8895738
references: Prog Cell Cycle Res. 1996;2:99-105
references: 9552387
references: Nucleic Acids Res. 1983 Mar 11;11(5):1475-89
references: 6828386
references: Cancer Res. 1995 Nov 15;55(22):5187-90
references: 7585571
references: Clin Cancer Res. 2001 Nov;7(11):3629-39
references: 11705886
references: Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3611-6
references: 12655051
references: Mol Cancer Ther. 2002 Oct;1(12):1067-78
references: 12481430
references: J Inorg Biochem. 1999 Oct;77(1-2):65-70
references: 10626356
references: Oncogene. 2001 Apr 5;20(15):1803-15
references: 11313928
references: Proc Natl Acad Sci U S A. 1998 May 26;95(11):6163-8
references: 9600935
references: Acta Oncol. 1998;37(4):355-63
references: 9743457
references: Cell Cycle. 2002 May-Jun;1(3):162-8
references: 12429926
references: Oncogene. 2003 Sep 1;22(37):5834-47
references: 12947390
references: Mol Cell Biol. 2005 Apr;25(7):2853-60
references: 15767688
references: Mol Cell Biol. 2001 Jul;21(13):4129-39
references: 11390642
references: Cancer Res. 1996 Feb 15;56(4):689-93
references: 8630996
references: Mol Pharmacol. 2001 Apr;59(4):725-31
references: 11259616
references: Anticancer Drug Des. 1994 Oct;9(5):389-99
references: 7945723
references: Trends Cell Biol. 1994 Jun;4(6):202-7
references: 14731678
references: Oncogene. 2005 Apr 21;24(18):2929-43
references: 15735718
references: Oncogene. 2007 Mar 22;26(13):1949-53
references: 17001315
references: Biochem Biophys Res Commun. 1992 Nov 16;188(3):1286-94
references: 1445361
references: Int J Oncol. 1998 Aug;13(2):225-32
references: 9664115
references: Neoplasia. 2001 Jan-Feb;3(1):10-6
references: 11326311
references: Cell. 1993 Nov 19;75(4):805-16
references: 8242751
references: Br J Cancer. 2006 Dec 4;95(11):1514-24
references: 17088910
references: Oncogene. 1995 Oct 5;11(7):1217-28
references: 7478541
references: J Biol Chem. 1992 Jul 5;267(19):13520-7
references: 1618852
references: Cancer Chemother Pharmacol. 1997;40(2):159-66
references: 9182838
references: Cancer Res. 1988 Aug 15;48(16):4484-8
references: 3395999
references: Cancer Res. 1993 Oct 1;53(19):4567-72
references: 8402629